Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BrainCells logo — Pioneering biopharmaceutical solutions to enhance neuron gro...

BrainCells

Pioneering biopharmaceutical solutions to enhance neuron growth and address CNS disorders with advanced clinical-stage programs

Founded 2003 Debt Financing Total: $73.68M Biotechnology, Health Care +1

General Information

Company Name BrainCells
Founded Year 2003
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Debt Financing
Social

Get notified when BrainCells moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BrainCells

BrainCells is a biopharmaceutical company founded in 2003 and headquartered in San Diego, California. The company's slogan - "Pioneering biopharmaceutical solutions to enhance neuron growth and address CNS disorders with advanced clinical-stage programs" - underscores its focus on developing innovative solutions for central nervous system (CNS) diseases. BrainCells is dedicated to creating compounds that promote the growth of new neurons for conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's product line includes BCI-838 and BCI-632, which work by enhancing synaptic glutamate through the inhibition of the mGlu2/3 auto-receptor. Additionally, BrainCells is actively building a robust pipeline of clinical-stage programs to target unmet medical needs in mood disorders, psychoses, cognitive issues, brain repair, and other CNS disorders. The company has received a $1.98M Debt Financing investment on 11 January 2012. This investment reflects the confidence of the investing party in BrainCells' innovative approach and the potential of its products to address critical unmet needs in the treatment of CNS disorders. With its strong focus on biotechnology and healthcare, BrainCells is positioned to make significant contributions to the advancement of treatments for neurological conditions, making it an intriguing prospect for venture capital firms seeking opportunities in the biopharmaceutical sector.

Taxonomy: Biopharmaceuticals, Neuroscience, Central Nervous System Disorders, Neuron Growth, Clinical-stage Programs, Major Depressive Disorder, Treatment-resistant Depression, Alzheimer's Disease, BCI-838, BCI-632, Synaptic Glutamate, mGlu2/3 Auto-receptor, San Diego, Drug Development, Neurological Disorders

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing •••••• - 11 Jan 2012
Debt Financing •••••• - 01 Aug 2011
Series B •••••• 2
Investor
•••• •••• 		01 Apr 2008
Series B •••••• 6
Investor Investor Investor Investor Investor Investor
01 Mar 2008
Series A •••••• 2
Investor Investor
15 Jul 2005

BrainCells Alternatives & Competitors

BrainCells vs
Azevan Pharmaceuticals
Azevan Pharmaceuticals

Innovative therapies for stress, mood, and behavior disorders

Series Unknown
5 employees
Biotechnology, Health Care
BrainCells vs
Clinilabs
Clinilabs United States

The CRO for CNS

262 employees
Biotechnology
BrainCells vs
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. United States

Creating breakthrough innovative therapeutics for serious CNS disorders

Series C
144 employees
Biopharma, Biotechnology
Also compare with: BrainCells vs Cerevel Therapeutics Cerevel Therapeutics

FAQ About BrainCells

Pioneering biopharmaceutical solutions to enhance neuron growth and address CNS disorders with advanced clinical-stage programs
BrainCells was founded in 2003.
BrainCells operates in the following industries: Biotechnology, Health Care, Medical Devices.
BrainCells has completed 5 funding rounds, raising a total of $73.68M. The latest funding stage is Debt Financing.
Top alternatives and competitors to BrainCells include Azevan Pharmaceuticals, Clinilabs, MapLight Therapeutics, Inc., Cerevel Therapeutics, Arvelle Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BrainCells and Azevan Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BrainCells and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy